Review
Biochemistry & Molecular Biology
Mara Carsote, Mihaela Stanciu, Florina Ligia Popa, Ana-Maria Gheorghe, Adrian Ciuche, Claudiu Nistor
Summary: This article provides an overview of the most recent data on primary hyperparathyroidism (PHP) in children and teenagers. The results cover a wide range of assessments and findings, highlighting the importance of understanding PHP in young patients.
Article
Surgery
Xin Li, Yao Lu, Ling Zhang, Aiping Song, Honglei Zhang, Bo Pang, Jun Liu, Xiaoliang Sun, Haoyang Ji, Linping Huang, Meng Yang
Summary: The expression of calcium-sensing receptor (CaSR) was found to be downregulated in both primary and secondary hyperparathyroidism (HPT). However, secondary HPT exhibited higher levels of CaSR mRNA and protein compared to primary HPT.
Editorial Material
Medicine, General & Internal
Zhenping Han, Tingting Li, Siyi Wang, Li Gao, Ying Hu, Yu Zhao, Jieping Yan
Summary: This case report describes a 52-year-old male patient diagnosed with multiple endocrine neoplasia type 1 (MEN1) through gastrinoma, parathyroid adenoma and gene detection. The patient had relapsed primary hyperparathyroidism (PHPT) and received ultrasound-guided radiofrequency ablation (RFA) as a treatment. The patient showed remarkable recovery after RFA for the relapsed PHPT. RFA may be considered as an alternative treatment for MEN1 patients with high surgical risk or those unwilling or unable to undergo surgery.
Review
Endocrinology & Metabolism
Fuqiong Chen, Qinqin Xu, Wenzhu Yue, Xuefeng Yu, Shiying Shao
Summary: This is a case report of hyperparathyroidism caused by MEN1 gene mutation. The patient was diagnosed with a mutation in the MEN1 gene through genetic analysis. The patient's condition improved after undergoing parathyroidectomy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Zhoujun Liu, Yueting Zhao, Xue Han, Xin Hu, Yuzhi Zhang, Lan Xu, Guofang Chen, Chao Liu, Shuhang Xu
Summary: This article reports a MEN1 patient with PHPT who was diagnosed through genetic screening. After parathyroidectomy, the patient still had abnormal levels of serum calcium and parathyroid hormone, but ultrasound-guided microwave ablation treatment resulted in normal levels, suggesting a good short-term prognosis.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Magnus Holm, Peter Vestergaard, Morten Moller Poulsen, Ase Krogh Rasmussen, Ulla Feldt-Rasmussen, Mette Bay, Lars Rolighed, Stefano Londero, Henrik Baymler Pedersen, Christoffer Holst Hahn, Klara Bay Rask, Heidi Hvid Nielsen, Mette Gaustadnes, Maria Caroline Rossing, Anne Pernille Hermann, Christian Godballe, Jes Sloth Mathiesen
Summary: Studies of primary hyperparathyroidism (PHPT) in multiple endocrine neoplasia type 2A (MEN 2A) have shown varying frequencies, definitions, and clinical characteristics. This nationwide population-based retrospective study provides a representative frequency and strict definition of PHPT in MEN 2A. The findings reveal a lower frequency and later onset of PHPT than previously reported, suggesting a milder course of the disease.
Review
Endocrinology & Metabolism
Elisabetta Lavezzi, Alessandro Brunetti, Valeria Smiroldo, Gennaro Nappo, Vittorio Pedicini, Eleonora Vitali, Giampaolo Trivellin, Gherardo Mazziotti, Andrea Lania
Summary: This article presents two cases of MEN4 and provides some indications for the management of these patients through a review of the current literature. According to the literature, hyperparathyroidism is the most common clinical feature of MEN4, followed by pituitary adenoma and neuroendocrine tumors. However, MEN4 appears to be a variant of MEN with milder clinical features and later onset.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Pharmacology & Pharmacy
B. Saravana-Bawan, J. D. Pasternak
Summary: This review article discusses the diagnosis and treatment of patients with multiple endocrine neoplasia type 2 (MEN2), including the most common tumors associated with MEN2 and additional manifestations. The review provides an overview of clinical manifestations, screening, diagnosis, treatment, and surveillance of patients with MEN2.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Medicine, General & Internal
Ying Wang, Sheng Cai, He Liu, Rui-Na Zhao, Xing-Jian Lai, Ke Lv, Yu-Xin Jiang, Jian-Chu Li
Summary: Patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism (MPHP) had higher levels of parathyroid hormone, more frequent multiglandular parathyroid disease and hyperplasia, and parathyroid lesions usually presented with a round shape on ultrasonography compared to those with sporadic primary hyperparathyroidism (SPHP). Over the last 5 years, more concurrent thyroid cancer was found in MPHP patients than in SPHP patients.
Article
Biochemistry & Molecular Biology
Tomohiro Saito, Masahide Mizobuchi, Mariko Sakai, Takehisa Kawata, Tetsuya Kitayama, Tadashi Kato, Taihei Suzuki, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: This study investigated the effect of calcimimetic evocalcet (Evo) on the expression of parathyroid calcium-sensing receptor (CaSR) and vitamin D receptor (VDR). The results showed that Evo and cinacalcet (Cina) can increase the expression of CaSR and VDR in uremic rats with secondary hyperparathyroidism (SHPT). The upregulation of these receptors may provide better control of mineral and bone disorder markers.
Article
Biochemistry & Molecular Biology
Tomohiro Saito, Masahide Mizobuchi, Mariko Sakai, Takehisa Kawata, Tetsuya Kitayama, Tadashi Kato, Taihei Suzuki, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: It has been found that the expression of calcium and vitamin D receptors is reduced during hemodialysis. However, treatment with calcimimetic evocalcet (Evo) can enhance the expression of these receptors in hemodialysis patients, which contributes to better control of mineral and bone disorder markers.
Review
Endocrinology & Metabolism
Abdallah Al-Salameh, Guillaume Cadiot, Alain Calender, Pierre Goudet, Philippe Chanson
Summary: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome characterized by the co-occurrence of primary hyperparathyroidism, duodenopancreatic neuroendocrine tumours (NETs) and/or pituitary adenomas. Patients with MEN1 should undergo tailored biochemical and imaging screening. Knowledge about the clinical phenotype of these tumours has progressed over the past 10 years, particularly in France and the Netherlands.
NATURE REVIEWS ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
An Song, Rong Chen, Wenmin Guan, Wei Yu, Yi Yang, Jiajia Wang, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, Ou Wang
Summary: This study compared the clinical characteristics, especially the skeletal involvement, between patients with MHPT and SHPT. The duration of disease in the MHPT group was longer, but the age at hospital visit was significantly lower. The proportion of skeletal involvement in the MHPT group was significantly lower, but among MHPT cases with normal BMD, there were still patients with bone microstructure damage.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Cell Biology
Francesca Marini, Francesca Giusti, Federica Cioppi, Davide Maraghelli, Tiziana Cavalli, Francesco Tonelli, Maria Luisa Brandi
Summary: This study evaluated the effect of parathyroidectomy on bone metabolism and bone mass in patients with MEN1 PHPT and sPHPT, confirming the efficacy of surgery in restoring normal hormone levels and improving bone mass. In MEN1 patients, surgery is strongly recommended to prevent early-onset bone mass loss in the presence of increased PTH and hypercalcemia.
Review
Rheumatology
Maroua Slouma, Maissa Abbes, Rim Dhahri, Noureddine Litaiem, Nour Gueddiche, Nada Mansouri, Issam Msekni, Imen Gharsallah, Leila Metoui, Bassem Louzir
Summary: Multiple endocrine neoplasia type 1 is a rare genetic syndrome that primarily affects endocrine tissues and has significant impact on the skeletal system. When pathological fractures occur in young patients, consideration should be given to diagnosis of this disease. Early intervention and treatment are crucial in preventing further skeletal damage.
CLINICAL RHEUMATOLOGY
(2021)